Scholars Central

CommentaryPublished 28 Jan 2022

T lymphocytes-based immunotherapy

Authors: Cloe Emily

Journal of Molecular Cancer

Volume 5 · Issue 1 · Pages 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Illusory Antigen Receptor T cell is a T lymphocyte-based immunotherapy, which accomplishes extraordinary triumphs in treating blood malignancies and gives new desire to sign progressed disease patients. Invariant Normal Executioner T (iNKT) cells are a sort of exceptional T lymphocytes portrayed by communicating invariant TCR of V24V11 to perceive CD1d-introduced glycolipid antigens, which span intrinsic and versatile invulnerable reactions. iNKT cells themselves show solid enemy of growth impact in cancer models by means of CD1d-intervened killing of CD1d-positive cancer cells and immunosuppressive TAMs and MDSCs, and are firmly connected with the guess of disease patients. iNKT cells are not confined to Polymorphic Human Leukocyte Antigen (HLA) and can forestall Graft Versus Host Disease (GvHD), which comes to be an optimal CAR vector for allogeneic treatment. In this survey, we summed up the current status of clinical use of iNKT cells and the most recent accomplishments of CAR-iNKT cells, which gives new understanding in CAR-iNKT advancement and uses.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Molecular Cancer.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Molecular Cancer
  • SubjectGenetics & Molecular Biology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Cloe Emily”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels